心血管-肾脏-代谢综合征可预测类风湿关节炎患者心血管事件:CARMA队列10年前瞻性分析
基于西班牙67家医院CARMA队列的10年前瞻性研究,纳入704例类风湿关节炎(RA)患者和604例对照,按美国心脏协会标准分类心血管-肾脏-代谢(CKM)分期。RA患者更多处于CKM 3-4期,CKM 4期较2期显著增加复合心血管事件或全因死亡风险(RA HR 3.90, 95%CI 2.29-6.64;对照 HR 5.22, 95%CI 2.39-11.40),且RA患者在CKM 2期时风险已显著高于同分期对照(HR 2.40, 95%CI 1.42-4.05)。
要点
- RA患者CKM分期分布显著差于对照,更多处于晚期(3-4期,p<0.001)。
- RA患者CKM 4期较2期复合心血管事件或全因死亡风险显著升高(HR 3.90)。
- RA患者CKM 2期时不良结局风险已显著高于同分期对照(HR 2.40)。
核心结论
- CKM综合征在RA患者中患病率高,且是心血管结局的决定因素。
研究设计与样本
- 西班牙67家医院前瞻性招募RA患者及无炎症性疾病对照,随访10年,按AHA共识定义CKM分期,采用年龄性别校正Cox模型分析CKM分期与复合心血管事件或全因死亡的关联。
主要发现
- RA患者704例、对照604例,CKM分期分布差异显著(p<0.001),对照更多为0-1期,RA更多为3-4期。
- 随CKM分期进展,RA和对照的复合心血管事件或全因死亡发生率均显著升高。
- RA患者CKM 4期较2期复合结局风险显著增加(HR 3.90;95%CI 2.29-6.64),对照同样升高(HR 5.22;95%CI 2.39-11.40)。
- RA患者CKM 2期不良复合结局风险显著高于同分期对照(HR 2.40;95%CI 1.42-4.05,p<0.001)。
关键数值与推荐
- CKM分期依据美国心脏协会共识定义。
- 复合结局为心血管事件或全因死亡。
- CKM 4期 vs 2期:RA HR 3.90(95%CI 2.29-6.64);对照 HR 5.22(95%CI 2.39-11.40)。
- RA CKM 2期 vs 对照CKM 2期:HR 2.40(95%CI 1.42-4.05,p<0.001)。
临床怎么用
- 对RA患者应评估CKM分期,识别晚期患者以强化心血管风险管理。
- RA患者处于CKM 2期时即需警惕心血管风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the prevalence of cardiovascular-kidney-metabolic (CKM) syndrome and the relationship with cardiovascular (CV) events in rheumatoid arthritis (RA) patients from the CARdiovascular in RheuMAtology (CARMA) project followed prospectively for 10 years. METHODS: Between July 2010 and January 2012, patients with RA and a comparison cohort of individuals without inflammatory diseases (controls) were recruited from 67 hospitals across Spain. CKM stage at recruitment was classified according to the American Heart Association consensus definition. Cox proportional hazards models adjusted for age and sex were used to evaluate the association between CKM stage and the composite outcome of CV events or all-cause mortality at 10-year follow-up. RESULTS: The study comprised 704 patients with RA and 604 controls followed prospectively for 10 years. The distribution of CKM stages differed significantly between two groups. Controls were more frequently classified in CKM stages 0 and 1, whereas RA patients predominated in advanced stages, particularly CKM stages 3 and 4 (p < 0.001). The incidence of CV events or all-cause mortality increased markedly with advancing CKM stage in both RA patients and controls. CKM stage 4 was associated with a significantly increased risk of composite outcome compared with CKM stage 2 in RA patients (Hazard ratio [HR] 3.90; 95% confidence interval [CI] 2.29-6.64) and controls (HR 5.22; 95% CI 2.39-11.40). RA patients classified as CKM stage 2 experienced a significantly higher risk of adverse composite outcome compared with controls at the same CKM stage (HR 2.40; 95% CI 1.42-4.05, p < 00.1). CONCLUSIONS: CKM syndrome has a high prevalence and is a determinant of CV outcomes in patients with RA.
引用
- González-Juanatey C, Llorca J, Castañeda S, et al. Cardiovascular-Kidney-Metabolic syndrome predicts the development of cardiovascular events in patients with rheumatoid arthritis: a 10-years prospective analysis from the CARMA cohort. Semin Arthritis Rheum. 2026. PMID: 42365792. doi:10.1016/j.semarthrit.2026.153027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。